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Hepatitis E virus (HEV) is a major human pathogen in much of the developing world. It is a plus-strand
RNA virus with a 7.2-kb polyadenylated genome consisting of three open reading frames, ORF1, ORF2, and
ORF3. Of these, ORF2 encodes the major capsid protein of the virus and ORF3 encodes a small protein of
unknown function. Using the yeast three-hybrid system and traditional biochemical techniques, we have
studied the RNA binding activities of ORF2 and ORF3, two proteins encoded in the 3 structural part of the
genome. Since the genomic RNA from HEV has been postulated to contain secondary structures at the 5 and
3 ends, we used these two terminal regions, besides other regions within the genome, in this study. Experi-
ments were designed to test for interactions between the genomic RNA fusion constructs with ORF2 and ORF3
hybrid proteins in a yeast cellular environment. We show here that the ORF2 protein contains RNA binding
activity. The ORF2 protein specifically bound the 5 end of the HEV genome. Deletion analysis of this protein
showed that its RNA binding activity was lost when deletions were made beyond the N-terminal 111 amino
acids. Finer mapping of the interacting RNA revealed that a 76-nucleotide (nt) region at the 5 end of the HEV
genome was responsible for binding the ORF2 protein. This 76-nt region included the 51-nt HEV sequence,
conserved across alphaviruses. Our results support the requirement of this conserved sequence for interaction
with ORF2 and also indicate an increase in the strength of the RNA-protein interaction when an additional 44
bases downstream of this 76-nt region were included. Secondary-structure predictions and the location of the
ORF2 binding region within the HEV genome indicate that this interaction may play a role in viral
encapsidation.
Hepatitis E virus (HEV), the causative agent of hepatitis E,
is transmitted via the fecal-oral route, predominantly through
contaminated water, and is responsible for sporadic infections
as well as large epidemics of acute viral hepatitis in developing
countries (3, 4, 11, 12, 13, 21, 22, 23, 36). The HEV genome
organization resembles that of many alphaviruses, with non-
structural genes at the 5 end and structural genes at the 3 end
(13, 23), and is currently classified in a separate unclassified
group of hepatitis E-like viruses (2). It has a single-stranded
positive-sense RNA genome of 7.2 kb with three forward open
reading frames (ORF1, ORF2, and ORF3) encoding three dif-
ferent proteins (Fig. 1A) (13, 24, 29, 31). The 5 untranslated
region (UTR) is 28 nucleotides (nt) in length, and bases 2
through 26 can potentially assume a complex secondary struc-
ture or hairpin (7). Bases 150 to 208 form a sequence that is
homologous to the 51-nt sequence, conserved across alphavi-
ruses. The 3 UTR is 68 nt long and has been postulated to
form stem-loop structures (29).
In the absence of a reliable culture system for HEV, funda-
mental studies of its replication and expression strategy have
been restricted to foreign gene expression systems. ORF2 and
ORF3 have been expressed in Escherichia coli, animal cells,
baculovirus, yeast and in vitro in a coupled transcription-trans-
lation system (6, 8, 9, 15, 19).
ORF1, the putative nonstructural gene, begins 28 nt from the
5 end of the HEV genome, spans 5,079 bases before termi-
nating at nt 5107, and codes for a polypeptide of 1,693 amino
acid residues. ORF2 starts from nt 5147, extends 1,980 bases
before ending at nt 7127, and codes for the major structural
protein of 660 amino acids (88 kDa) that is expressed intra-
cellularly as well as on the cell surface. It is synthesized as a
precursor and is processed through signal sequence cleavage
into the mature protein, which is capable of self-association
and glycosylation (10, 30, 32). The third positive-polarity read-
ing frame of 369 bases (ORF3) overlaps ORF1 at its 5 end by
1 nt, significantly overlaps ORF2 (in a different frame), and
codes for a protein of 123 amino acids (13.5 kDa). ORF3
encodes a phosphoprotein that is expressed intracellularly,
fractionates with the cytoskeletal and membrane fractions, and
shows no major processing (1, 20, 37). The ORF3 protein
dimerizes using a 43-amino-acid interaction domain, interacts
with proteins containing SH3 domains, and activates mitogen-
activated protein kinase (14, 32). Recently, we have shown that
the phosphorylated form of the ORF3 protein interacts with
the nonglycosylated form of the major capsid protein, ORF2 of
HEV (34).
Since HEV is a plus-strand RNA virus, it is expected that
either one of the two proteins encoded in the structural part of
the genome, ORF2 or ORF3, would fulfill the role of genomic
RNA binding for viral encapsidation leading to headfull pack-
aging of new HEV particles in the infected hepatocyte. This
fundamental aspect of the HEV life cycle has not yet been
elucidated.
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We have used the yeast three-hybrid system (26) to detect
the RNA binding properties of these two proteins of HEV and
map the interaction domains for the interacting protein and
genomic RNA. The yeast three-hybrid system is a genetic assay
in which specific RNA-protein interactions can be detected
rapidly in yeast, in a fashion that is independent of the biolog-
ical role of the RNA or protein. This approach is based on the
yeast two-hybrid system, in principle, which detects protein-
protein interactions. The three-hybrid system allows simple
phenotypic properties of yeast, such as the ability to grow or to
metabolize a chromogenic compound, to be used to detect and
analyze an RNA-protein interaction. In the cotransformed
yeast cell, a fusion RNA molecule bridges two hybrid proteins,
one containing a DNA binding domain and the other contain-
ing a transcriptional activation domain, resulting in the tran-
scriptional activation of HIS3 and lacZ reporter genes down-
stream of the binding site for the DNA binding domain. To
apply this system to HEV, we designed constructs fusing MS2-
RNA with the 5 HEV (nt 1 to 910) genome and the 3 HEV
(nt 6807 to 7184) genome in two separate constructs (Fig. 1B).
The HEV ORF2 and ORF3 genes were cloned in-frame with
the Gal4 activation domain (Gal4 AD) (Fig. 1C) in two sepa-
rate constructs.
From the two ORFs tested, using the yeast three-hybrid
assay, we found the ORF2 protein to be capable of binding to
the 5 end of the HEV genome. These results were verified by
electrophoretic mobility shift assays (EMSA). Further, we have
mapped the interaction domains of the genomic RNA and the
FIG. 1. HEV genome and yeast three-hybrid constructs used to study RNA-protein interactions. (A) Genes and genome organization of HEV.
Start sites for all three ORFs and both 3 and 5 UTRs are shown in red. A(n) represents the poly(A) tail (blue). Predicted stem-loop structures
(SL) are shown schematically and numbered across the HEV genome. (B) Fusion RNA constructs designed to express fusion transcripts within
the yeast cell. The MS2 RNA coding region (yellow) was cloned with two different HEV genomic regions (green). Predicted mRNA stem-loop
structures are shown schematically as fusion transcripts. (C) Hybrid protein constructs to test the RNA binding activity of the ORF2 and ORF3
proteins of HEV using the yeast three-hybrid system. The schematic diagram shows the Gal4 Gal4 AD fused in frame to the ORF2 and ORF3
genes of HEV, thus expressing fusion proteins in yeast cells. (D) Schematic diagram of the yeast three-hybrid system showing the different
fusion-RNA and hybrid-protein constructs being examined. P, promoter; Ter, terminator; SL, stem-loop structure.
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interacting protein, ORF2. Deletion analysis of ORF2 showed
that the RNA binding activity of the protein was lost when
deletions were made beyond amino acid 111 from the N ter-
minal, suggesting that its RNA binding activity is secondary-
structure dependent rather than sequence specific. On the
other hand, finer mapping of the 5 genomic RNA revealed
that a 76-nt region was responsible for this interaction. Al-
though this 76-nt region was the smallest identifiable interac-
tion domain that binds ORF2, genomic sequences up to 44 nt
downstream of this region contributed to the strengthening of
the RNA protein interaction. A detailed RNA secondary-
structure model for the interaction domain has been postu-
lated, and the functional significance of this interaction during
the viral life cycle has been discussed.
MATERIALS AND METHODS
Growth media, yeast strains, and plasmids. Yeast cells were grown either in
synthetic media lacking the indicated nutrients or in rich media (25). The com-
ponents for the three-hybrid selection were provided by the laboratory of M.
Wickens (University of Wisconsin, Madison), and the selection was performed
essentially as described elsewhere (26, 27, 38). The yeast strains, plasmids, and
plasmid constructs used in this study are listed in Table 1.
Yeast three-hybrid techniques. The yeast host strain L40-coat constitutively
expresses the LexA-MS2 hybrid coat protein in which the LexA DNA binding
domain is at the N terminal and the MS2 coat protein is at the C terminal. Both
the RNA plasmid (pIIIMS2-2) and its fusion constructs and the AD vector
(pACTII) and its hybrid protein constructs were transformed in corresponding
pairs to study RNA-protein interactions (Fig. 1D). HIS3 and lacZ serve as
reporter genes for the three-hybrid assay. -Galactosidase expression levels were
determined either by a 5-bromo-4-chloro-3-indolyl--D-galactoside (X-Gal) filter
assay or by a liquid assay using o-nitrophenyl-D-galactoside (5, 35, 36). Constructs
MS2-IRE RNA, in which the MS2 protein is 5 of the iron response element
(IRE) and construct AD-IRP, in which the iron regulatory protein (IRP) is
cloned in frame downstream of the activation domain (AD), have been used as
a positive control for the yeast three-hybrid experiments (26).
Gel shift assay (EMSA). EMSA was performed as described by Martin et al.
(17). Uniformly 32P-labeled RNA was produced by T7 RNA polymerase
transcription from inserts cloned into the pGEMT Easy plasmid (Promega)
and purified using the RN Easy kit (Qiagen). Purified probes were checked on
a 6% urea–acrylamide gel to verify the integrity of RNA transcripts. Full-
length ORF2 and ORF3 proteins and deletions of ORF2 were produced using
an in vitro-coupled transcription-translation rabbit reticulocyte system (Pro-
mega) and verified by immunoprecipitation with anti-ORF2 and anti-ORF3
antibodies.
To detect RNA-protein interactions by EMSA, 8 g of total protein was mixed
with 50,000 cpm of uniformly 32P-labeled RNA and 20 g of yeast tRNA and
incubated for 20 min in 10 mM Tris-HCl (pH 7.5)–50 mM KCl–1 mM dithio-
threitol–10% glycerol in 20 l on ice. Reaction products were analyzed by
electrophoresis on native 5 or 4% polyacrylamide gels using 50 mM Tris-glycine
as a buffer and visualized by autoradiography. Mock lysates were incubated along
with the labeled probe in a similar manner to rule out the possible binding of
endogenous protein from the rabbit reticulocyte lysate (data not shown). For
competitor binding assay, a 100-fold excess of unlabeled RNAs was incubated
along with the regular reaction mixture described above.
RNA secondary-structure analysis. RNA secondary structure was analyzed
using the mfold program (http://bioinfo.rpi.edu/applications/mfold/old/RNA),
based on minimum free energy calculations at 25°C.
TABLE 1. Yeast strains, plasmids, and recombinant plasmid constructs used in this study
Strain, plasmid, or constructa Genotype and description
Strain
L40-coat........................................................MATa ura3-52 leu2-3,112 his3200 trp11 ade2 LYS::(LexA op)-HIS3 ura3::(LexA-op)-LacZ, LexA-
MS2 coat (TRP1)
Plasmids
pACT2 ..........................................................GAL4 AD vector [GAL4(768–881)]; LEU2, 2m, Ampr
pIII/MS2-2....................................................Derived from pIIIEx426RPR
Constructs
pAS2-ORF2 .................................................pMT-ORF2 digested with NcoI and BamHI, fragment ligated
pACT-ORF2................................................pAS2-ORF2 digested with NcoI and BamHI, fragment ligated
pSG112-660 ORF2......................................Described in reference 8
pACT-ORF2 112-660 .................................pSG-ORF2 1–110 digested with EcoRI and BamHI, fragment religated
pACT-ORF2 1-226 .....................................pACT-ORF2 digested with EcoRI, vector religated
pACT2-ORF2 1-358 ...................................pACT2-ORF2 digested with NcoI and ScaI, fragment religated
pACT2-ORF2 1-586 ...................................pACT2-ORF2 digested with BstXI and NcoI and religated
pSG-ORF2 ...................................................Described in reference 8
pSG-ORF2 1-226 ........................................pSG-ORF2 digested with EcoRI and PstI, fragment religated
pSG-ORF2 1-358 ........................................pSG-ORF2 digested with ScaI and PstI, fragment religated
pSG-ORF2 1-586 ........................................pSG-ORF2 digested with BstXI and PstI, fragment religated
pSGIb ............................................................pSGI vector digested with EcoRI and HindIII, blunt ended, and vector religated
pSG-ORF2b..................................................pSG-ORF2 digested with PstI and BamHI, fragment religated into pSGIb
pSG-ORF2 228-660 ....................................pSG-ORF2b digested with BstEII and EcoRI, blunt ended, and vector religated
pIIIMS2-2 10-910 HEV ..............................Full-length HEV genome digested with SmaI and NdeI, fragment religated
pIIIMS2-1-250 HEV....................................Fragment from bp 1 to 250 PCR amplified and cloned into SmaI site of vector
pIIIMS2-2 1-130 HEV ................................Fragment from bp 1 to 130 PCR amplified and cloned into SmaI and ShpI site of vector
pIIIMS2-2 1-120 HEV ................................Fragment from bp 130 to 250 PCR amplified and cloned into SmaI and ShpI sites of vector
pGEMTeasy 1-250 HEV ............................Fragment from bp 1 to 250 PCR amplified and cloned using TA overhang ligation
pGEMT easy 130-250 HEV .......................pGEMT easy 1–250 digested with StuI and PstI, fragment religated
pGEMT 3 6807-7184 HEV .......................Fragment of 377 bp PCR amplified from pSG-ORF2 and cloned into pGEMT Easy vector
pMS2-2 3 6807-7184 HEV ........................Fragment of 377 bp PCR amplified from pSG-ORF2 and cloned into SmaI site of vector
pSG-ORF3 ...................................................Described in reference 8
pACT ORF3................................................pSG-ORF3 digested with SmaI and XhoI, fragment religated
a Numbers in italics represent the RNA sequence of the HEV genome.
b Intermediate vector constructs.
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RESULTS
The 5 end of the HEV genomic RNA interacts with the
ORF2 protein. The different regions of the HEV genome were
cloned into yeast three-hybrid vectors so as to express fusion
RNA transcripts in yeast cells. The 5 end (bases 1 to 910) of
the HEV genome was cloned into the pIIIMS2-2 yeast three-
hybrid vector (Table 1). Similarly, the 3 end (bases 6807 to
7184) and the 572 nt from the middle region (bases 5108 to
5680) of the HEV genome were cloned into the pIIIMS2-2
yeast three-hybrid vector (Table 1). All the constructs were
transformed into the L40-coat yeast three-hybrid host strain
and grown on auxotrophic media. Independent transformants
were picked and their total RNA was isolated. Transcription of
the fusion RNA was checked by reverse transcription-PCR
analysis. Further verification of the fusion RNA was performed
by cloning each insert into the SmaI site of the IRE sequence
in the pIIIMS2-2 vector (26) and checking for an interaction
between IRE and IRP in the presence of 25 mM 3-aminotria-
zole (3-AT) on SD-His growth medium (see the legend to Fig.
2) by using the yeast three hybrid system (data not shown).
3-AT was used to measure the strength of the RNA-protein
interaction. Similarly, full-length ORF2 and ORF3 genes were
cloned in frame with the Gal4 activation domain to express
hybrid proteins in the yeast cells as reported previously (32, 33,
34).
Single transformants and cotransformants were obtained in
different combinations and tested for RNA-protein interac-
tions (Fig. 2). The host yeast strain (L40-coat) showed negli-
gible background His phenotype. When singly transformed
host cells were analyzed, low background reporter gene activity
was detected on His plus 5 mM 3-AT medium and in -ga-
lactosidase assays. The MS2-5HEV/AD-ORF2 cotransfor-
mants clearly showed strong His prototrophy up to 15 mM
3-AT. This clone was strongly positive when tested for -ga-
lactosidase activity, in both filter and liquid assays. However,
the MS2-3HEV/AD-ORF2 cotransformants showed no re-
porter gene activity. The HEV genomic RNA (nt 5108 to 5680)
was also tested for interaction with AD-ORF2 and AD-ORF3.
Both assays gave negative results (data not shown). Similarly,
AD-ORF3, when cotransformed separately with MS2-5 HEV
and MS2-3HEV, failed to show increased reporter gene ac-
tivity.
The protein binding domain was subsequently shortened to
nt 1 to 250nt from nt 1 to 910, subcloned into the pIIIMS2-2
vector (Table 1), and checked for interaction with ORF2. Since
this shorter RNA region showed positive interaction with the
FIG. 2. Results from the three-hybrid analysis showing 5 HEV genomic RNA interacting with the ORF2 protein. YPD, yeast extract peptone
dextrose media (nonselective); Leu, Ura, LU represent SD-Leu (synthetic dextrose complete medium lacking leucine), SD-Ura (synthetic
dextrose complete media lacking uracil), and SD-Leu Ura synthetic growth media. LUHis3-AT (synthetic dextrose complete media lacking
histidine, leucine, and uracil with 3-aminotrizole) represents SD-Leu Ura His synthetic medium with 0, 5, 10, and 25 mM 3-aminotrizole
(3-AT) added. F represents results from the -galactosidase filter assay, and the bar graph represents relative -galactosidase units from the liquid
-galactosidase assay. L40-coat is the untransformed yeast host strain. MS2-IRE/AD-IRP is the postive control used in the assay (26).
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ORF2 protein, albeit of equal strength, subsequent EMSA
experiments were performed using this nt 1 to 250 5 HEV
RNA. The 5 and 3 regions of the HEV genome were tran-
scribed as 32P-labeled transcripts and, after purification, were
incubated with unlabeled ORF2 protein in separate tubes. As
negative controls, the 32P-labeled transcripts from the 5 and 3
genomic regions of HEV were analyzed separately on a non-
denaturing 6% polyacrylamide gel. Clearly, the 5 HEV
genomic transcript containing nt 1 to 250 showed a mobility
shift, indicating that the ORF2 protein was interacting with it
(Fig. 3, lanes 2 and 3), in contrast to lane 1, where no protein
was present. On the other hand, the 3 genomic region and the
nt 5108 to 5680 midgenomic region of HEV showed no binding
to the ORF2 protein (lane 4). Similar experiments were re-
peated with the ORF3 protein, which showed a negative inter-
action with both the 5 and 3 genomic regions of HEV (data
not shown).
A competitor binding assay was performed to study the
specificity of the interaction of the ORF2 protein with 5
HEV RNA (nt 1 to 250). In this experiment, unlabeled 3
HEV RNA (nt 6807 to 7184) was used as a nonspecific
competitor at a 100-fold higher molar concentration (Fig. 4,
lane 1). The 3 HEV RNA (nt 6807 to 7184) did not com-
pete for binding with the labeled 5 HEV RNA (nt 1 to
250)–ORF2 complex, which was visible on the autoradio-
gram. When unlabeled 5 HEV RNA (nt 1 to 250) at 100-
fold higher molar concentrations was incubated with labeled
5 HEV RNA (nt 1 to 250) and unlabeled ORF2 protein, it
competed with the labeled 5 HEV RNA (nt 1 to 250). This
was evident by the complete disappearance of signal (lane
2). Appropriate positive and negative controls are shown in
lanes 3 and 4, respectively. This experiment shows clearly
that the RNA-protein interaction was specific to the 5 HEV
RNA (nt 1 to 250) transcript and full-length ORF2 protein.
We further designed deletions to identify the interaction
domain of ORF2 responsible for RNA binding.
The N-terminal 111-amino-acid-deleted ORF2 protein in-
teracts with 5 HEV genomic RNA. The full-length ORF2 pro-
tein was subject to a series of deletions. These deletion pro-
teins were subsequently cloned in-frame with the Gal4
activation domain using the vector pACT2, as described in
Table 1. When tested for yeast three-hybrid interactions with
5 HEV RNA (nt 1 to 910), the constructs, AD-ORF2(1–227),
AD-ORF2(1–358), AD-ORF2(1–586), and AD-ORF2(228–
660) were negative. Only AD-ORF2(112–660), when tested
with 5 HEV RNA (nt 1 to 910) showed positive on the three-
hybrid analysis. All three hybrid cotransformants were tested
with increasing levels of 3-AT on His media and in -galac-
tosidase filter and liquid assays (Fig. 5A). Although the pres-
ence of 5 HEV RNA (nt 1 to 910) interactions with the
AD-ORF2(1–227), AD-ORF2(1–358), and AD-ORF2(1–586)
points toward the importance of the C-terminal region of the
protein, AD-ORF2(228–660) did not show a positive interac-
tion. This result points to an observation we have made in the
past (33, 34) regarding the ORF2 protein, i.e., that its proper-
ties are lost when it is truncated beyond amino acid 111 from
the N-terminal end.
Results obtained from the yeast three-hybrid system were
FIG. 3. In vitro gel shift assay confirming the results of the yeast
three-hybrid system. 5 HEV RNA (nt 1 to 250) and 3HEV RNA (nt
6807 to 7184) were 32P radiolabeled. ORF2 protein was produced
using a coupled transcription-translation system. The arrow shows
ORF2 protein bound to 32P-labeled RNA (lanes 2 and 3). Lanes 1 and
4 are negative controls. Asterisks refer to 32P labeled transcripts.
FIG. 4. Competitor binding assay. The ORF2 protein used in this
experiment is unlabeled. Lane 1 contains a nonspecific competitior, 3
HEV RNA (nt 6807 to 7184). Lane 2 contains a 100-fold excess of
unlabeled 5HEV RNA (nt 1 to 250) transcript. Lanes 3 and 4 are
positive and negative controls, respectively. Asterisks refer to 32P-
labeled transcripts. Nonradioactive transcripts 3 HEV RNA (nt 6807
to 7184) and 5 HEV RNA (nt 1 to 250) were used at 100-fold higher
molar concentrations.
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verified by conventional in vitro techniques. All ORF2 dele-
tions were expressed in a coupled transcription-translation sys-
tem, checked for expressed protein (as shown in Fig. 5B), and
used for EMSA with the 5 HEV RNA transcript (Fig. 5c).
Results obtained from EMSA exactly matched our observa-
tions from the yeast three-hybrid system, proving that only the
full-length protein and the ORF2(112–660) deletion were ca-
pable of interacting with the 5 genomic RNA. Due to the
inherent property of the ORF2 protein losing its RNA binding
activity when truncated beyond the N-terminal amino acid 111,
we were unable to perform a finer mapping of the interaction
domain for the ORF2 protein.
FIG. 5. Mapping the interaction domain for the ORF2 protein. (A) Amino acids 112 to 660 from the ORF2 protein are required for interaction
with the 5 HEV RNA (nt 1 to 910) region. Dotted boxes represent the AD regions which were fused in frame with the ORF2 protein (full length
or deletions) shown in boxed regions with vertical lines. Checkered boxes show the MS2 regions fused with the 5 HEV RNA (nt 1 to 910), shown
as horizontal lines. Open boxes represent regions that were deleted from ORF2. The numbers above the boxed regions with vertical lines represent
the first and last nucleotides of the regions included in the ORF2 deletion constructs. YPD, yeast extract peptone dextrose media (nonselective);
LU, SD-Leu Ura synthetic growth medium; LUHis3-AT, SD-Leu Ura His synthetic medium with 0, 5, 10, and 25 mM 3-AT added.
F represents results from the -galactosidase filter assay, and the bar graph represents relative -galactosidase units from the liquid -galactose
assay. (B) Control gel showing ORF2 deletions expressed using a coupled transcription-translation expression system. Major bands show the
expressed protein of interest and correspond to their calculated molecular masses. Weaker bands in each lane show nonspecific translation of rabbit
reticulocyte proteins. (C) EMSA showing ORF2(112–660) interacting with the 5 genomic region of HEV. Asterisks refer to 32P-labeled transcript.
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A 76-nt conserved domain from the 5 HEV genomic RNA
interacts with the ORF2 protein. The 5 HEV RNA (nt 1 to
910) was subcloned into smaller fragments. 5 HEV RNA (nt
1 to 250), 5 HEV RNA (nt 1 to 130), 5 HEV RNA (nt 130 to
250), and 5 HEV RNA (nt 130 to 206) were deletions of the
full-length 5 HEV RNA (nt 1 to 910) as described in Table 1.
Each of these deletions was individually tested for interaction
with the AD-ORF2 protein in the yeast three-hybrid assay plus
EMSA. Interestingly, the 5 HEV RNA (nt 1 to 250) transcript
showed a positive interaction, as had been observed with our
EMSA results described in the previous experiments. Subse-
quently, the two deletion transcripts, 5 HEV RNA (nt 1 to
130) and 5 HEV RNA (nt 130 to 250), which split the region
from nt 1 to 250, were tested for interaction with ORF2. From
this pair, the 5HEV RNA (nt 130 to 250) transcript interacted
with ORF2 (Fig. 6A). The 5 HEV RNA (nt 130 to 250)
region, consisting of 120 bases, showed a considerably stronger
interaction with the ORF2 protein compared with that of the
5 HEV RNA (nt 130 to 206) region, consisting of only 76
nucleotides (Fig. 6B). Hence, the nt 130 to 206 (76 nt) of the
HEV genome may contain the major interaction domain re-
quired for binding to ORF2; however, genomic sequences 44
nt downstream of this region contribute significantly to an
increase in the strength of this RNA-protein interaction sig-
nificantly.
DISCUSSION
We have used the yeast three-hybrid system to show that the
ORF2 protein of HEV is capable of binding its viral genome at
the 5 end. The ORF3 protein does not possess this activity.
Also, the ORF2-RNA interaction is specific to the 5 end of
the HEV genome and not to the 3 end or any other region
tested. Finally, we have mapped the ORF2 protein binding
region on the RNA genome to a 76-nt region [5 HEV RNA
(nt 130 to 206)]. This 76-nt region of the viral genome is
capable of binding the full-length ORF2 protein and its N-
terminal deletion from nt 1 to 111 as well. Our previous ob-
servations of the dimerization of ORF2 (33) and its heterotypic
interaction with ORF3 (34) have shown similar results, sug-
gesting that the ORF2 protein loses its activity when truncated
beyond amino acid 111 from the N terminus.
We used the mfold program to predict the RNA secondary
structure for the HEV genomic region from nt 130 to 250
(which includes the 76-nt region plus the downstream 44 nt),
based on minimum free energy calculations (Fig. 7). Interest-
ingly enough, the 76-nt region, which we have shown to be
responsible for binding the ORF2 protein, completely encom-
passes the HEV homologue of the alphavirus consensus 51-nt
sequence (bases 150 to 208) (18, 20). This 51-nt conserved
FIG. 6. Mapping the interaction domain for the 5HEV RNA. (A) Mapping of the interaction domain of the 5HEV RNA (nt 1 to 910) region.
The hatched box represents the alphavirus consensus sequence. Plus signs shows a summarized result of the yeast three-hybrid interactions.
(B) EMSA for the different RNA deletions from the 5 HEV genome. Asterisks refer to 32P-labeled transcript.
FIG. 7. Secondary-structure prediction of the 5 HEV genomic re-
gion from nt 130 to 250. Numbers correspond to the numbers on the
HEV genome. SL I, SL II, and SL III represent the three stem-loop
structures shown in the figure. The highlighted region represents the
51-nt conserved region from alphaviruses.
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region is highlighted and is part of two stem-loop structures
(SLI and SLII), similar to other alphaviruses such as Sindbis
virus (18), Highlands J virus (28), and Semliki Forest virus
(28). Looking at the secondary structures, it becomes obvious
that sequences downstream of base 208 contribute to the
strength of SLII. Our experimental data on the HEV RNA-
ORF2 protein interaction fall in line with the in silico second-
ary-structure prediction, suggesting that sequences down-
stream of base 208 contribute to increased strength of SLII,
thus strengthening the RNA-protein interaction. The 4-nt re-
gion (nt 209 to 212 in SLII) may not be essential for the
RNA-protein interaction but may contribute to increasing the
binding strength of the RNA-protein interaction in question.
The 5 HEV region from nt 130 to 250 also forms a third
stem-loop structure (SLIII). Although not essential, this stem-
loop structure may contribute significantly toward increasing
the overall strength of the HEV genomic RNA-ORF2 protein
interaction.
Since HEV is a plus-strand RNA virus, one of its structural
proteins is required to show RNA binding activity for two
essential viral functions - viral replication and packaging of its
genome into the capsid during viral assembly. Since ORF2 is
the major capsid protein, it would be the most likely candidate
to bind the genomic RNA for viral packaging. We have exper-
imentally shown that the ORF2 protein binds to the 5-termi-
nal region of the viral genome, thus becoming the most likely
candidate to perform this biological function.
HEV is postulated to form subgenomic RNA transcripts
(3.7 and 2 kb) from the 3 (structural) region of the ge-
nome (16). Hence, it seems like a good strategic option for the
virus to have its RNA encapsidation signal at the 5 end of the
genome. This will result in only the full-length genomic RNA
(7.2 kb) being differentially recognized by the capsid protein
ORF2 for headfull packaging during viral assembly in the
hepatocyte.
Although data presented in this publication point to a fun-
damental viral process, i.e., genome encapsidation, and
strongly indicates the possibility that the ORF2 protein may be
responsible for bringing the genomic RNA into the capsid
during assembly, direct biological evidence is difficult to obtain
due to the absence of an in vitro culture system for HEV.
Indirect approaches using mutational knockout of the identi-
fied interaction domain and restoration by complementary mu-
tations are under investigation.
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